BJMO - volume 14, issue 8, december 2020
L-A. Teuwen MD, PhD, M. Peeters MD, PhD, T. Vandamme MD, PhD, H. Prenen MD, PhD
The annual ESMO meeting was held virtually between 19th and 21st September 2020 and covered many interesting abstracts in the field of digestive oncology. In this overview, our main aim was to highlight the data that are most relevant for daily clinical practice. This year, we will discuss the results according to the traditional division in upper and lower gastro-intestinal tract tumours.
Read moreBJMO - volume 14, issue 8, december 2020
T. Rawson MSc, J. Blokken PhD, PharmD, Tom Feys MBA, MSc
In this overview, the key highlights from ESMO 2020 with respect to gynaecological cancers will be discussed. In advanced endometrial cancers, data were presented on the use of letrozole in combination with palbociclib. In addition, to this, promising clinical efficacy was seen for the antibody-drug conjugate tisotumab vedotin in the treatment of patient with recurrent or metastatic cervical cancer. Also in cervical cancer, a study was presented on the optimal management of cervical cancer patients with intraoperatively detected positive pelvic lymph nodes. In ovarian cancers, several updates were presented of pivotal trials evaluating PARP inhibitors. In addition, results if the phase III INOVATYON trial indicate that platinum-based regimens should remain the standard of care for patients with recurrent ovarian cancer who experienced disease progression within six-twelve months after their last line of platinum-based therapy. Finally, results were presented of the IMagyn050 trial assessing the efficacy and safety of bevacizumab in combination with atezolizumab in the treatment of patients newly diagnosed stage III-IV ovarian cancer.
Read moreBJMO - volume 14, issue 7, november 2020
H. Van Poppel MD, PhD
In light of the emergence and impact of COVID-19, the European Association of Urology (EAU) redesigned its 35th Annual EAU Congress (EAU20) into two online events, EAU20 Virtual Congress and EAU20 Theme Week, which took place from 17 to 19 July 2020 and from 20 to 26 July 2020, respectively. This article is an abridged version of the events’ oncology updates featured in the peer-reviewed conference report of the Medicom Medical Publishers.
BELG J MED ONCOL 2020;14(7):364-7)
Read moreBJMO - volume 14, issue 6, october 2020
W. Lybaert MD, T. Vandamme MD, PhD, G. Boons , L. De Backer , M. Peeters MD, PhD, NETwerk Antwerpen-Waasland , ENETS Centre of Excellence
The 17th Annual European Neuroendocrine Tumour Society (ENETS) Congress took place as a virtual meeting from March 11th until March 13th, 2020. This article will provide you with the highlights discussed at the meeting.
Read moreBJMO - volume 14, issue 5, september 2020
H. Prenen MD, PhD, T. Vandamme MD, PhD, M. Peeters MD, PhD
At this years’ virtual annual ASCO meeting, a wide range of interesting studies in the field of gastrointestinal (GI) cancer were presented. The aim of this overview is to discuss the most important of these studies, with a particular focus on data that have the potential to be practice changing. For practical reasons, this report will not follow the traditional subdivision in cancers from the upper and lower GI tract, but will rather focus on three major therapeutic strategies: neoadjuvant therapy, immunotherapy and targeted therapy.
(BELG J MED ONCOL 2020;14(5):183-7)
Read moreBJMO - volume 14, issue 5, september 2020
J. Blokken PhD, PharmD, Tom Feys MBA, MSc, H. Wildiers MD, PhD
During the 2020 Virtual ASCO meeting, no less than 226 presentations were dedicated to breast cancer. It is beyond the scope of this article to discuss all these abstracts, but instead we try to focus on the data that are most relevant for your daily clinical practice.
(BELG J MED ONCOL 2020;14(5):191-200)
Read moreBJMO - volume 14, issue 5, september 2020
J. Vansteenkiste MD, PhD, E. Wauters MD, PhD
ASCO 2020 featured the presentation of many interesting studies in the field of lung cancer. For early stage non-small cell lung cancer (NSCLC), there was a focus on adjuvant targeted therapy while for advanced NSCLC without oncogene addiction much attention went to first-line immunotherapy and to the use of novel antibody-drug conjugates. In addition to this, several trials discussed the potential of EGFR-tyrosine kinase inhibitor (TKI) combinations, the targeting of MET alterations or RET fusions and the search for EGFR exon 20 mutant selective drugs for patients with advanced NSCLC and oncogene addictions. Finally, this overview will describe important results in the field of non-metastatic and metastatic small-cell lung cancer (SCLC) as well as advances in mesothelioma.
(BELG J MED ONCOL 2020;14(5):201-8)
Read more
Top
